头孢他啶联合氨茶碱治疗慢性阻塞性肺气肿的疗效及对血清IGF-1、α1-AT、PDGF-B水平的影响

Effects of Ceftazidime Combined with Aminophylline on Chronic Obstructive Emphysema and Its Effect on the Serum IGF-1, α1-AT and PDGF-B Levels

目的:探讨头孢他啶联合氨茶碱治疗慢性阻塞性肺气肿(COPD)的临床疗效及对患者血清胰岛素样生长因子-1(IGF-1)、血清α1-抗胰蛋白酶(α1-AT)、血小板衍生生长因子-B(PDGF-B)水平的影响。方法:选择我院2015年4月至2018年4月收治的154例慢性阻塞性肺气肿作为研究对象,采用随机数字表法将其分为观察组与对照组。对照组采用头孢他啶治疗,观察组在对照组基础上加用氨茶碱联合治疗。对比两组患者的临床疗效、治疗前后血清IGF-1、α1-AT、PDGF-B水平的变化及不良反应的发生情况。结果:治疗后,观察组与对照组临床疗效总有效率分别为94.80%和71.43%,观察组显著高于对照组(P<0.05);观察组血清IGF-1、PDGF-B水平均显著低于对照组[(110.67±13.58) vs.(143.17±15.74)ng/ml、(128.67±15.33) vs.(247.69±30.17)ng/L],而血清α1-AT水平明显高于对照组[(2.79±0.43) vs.(1.77±0.46)g/L](P<0.05);观察组与对照组不良反应率分别为5.19%和50.64%,观察组明显低于对照组(P<0.05)。结论:综上所述,头孢他啶联合氨茶碱治疗COPD的临床疗效和安全性均显著优于单用头孢他啶治疗,可能与其有效降低COPD患者血清PDGF-B、IGF-1,明显提高血清α1-AT水平有关。

Objective: To investigate the clinical efficacy of ceftazidime combined with aminophylline in the treatment of chronic obstructive emphysema and the effect on the serum insulin-like growth factor-1, serum 1-antitrypsin and platelet-derived growth factor-b levels. Methods: 154 cases of patients with chronic obstructive emphysema admitted to our hospital from April 2015 to April 2018 were selected and were divided into the observation group and the control group by random number table method. The control group was treated with ceftazidime, and the observation group was treated with aminophylline on the basis of control group. The clinical efficacy, changes of serum IGF-1,α1-AT and PDGF-B levels before and after treatment and the occurrence of adverse reactions were compared between the two groups. Results: After treatment, the total effective rates of observation group and the control group were 94.80% and 71.43% respectively, and which was significantly higher in the the observation group than that of the control group(P<0.05). The serum IGF-1 and PDGF-B levels in the observation group were significantly lower than those in the control group [(110.67 13.58) vs.(143.17 15.74)ng/mL,(128.67 15.33) vs.(247.69 30.17)ng/L], while serum α1-AT level was significantly higher than that in the control group [(2.79 0.43) vs.(1.77 0.46)g/L](P<0.05). The incidence of adverse reactions in the observation group and the control group were 5.19% and 50.64% respectively, which were significantly lower in the observation group than that of the control group(P<0.05). Conclusion: The clinical efficacy and safety of ceftazidime combined with aminophylline in the treatment of COPD are significantly better than that of ceftazidime alone, which may be related to the effective reduction of serum PDGF-B and IGF-1 levels and the significant increase of serum α1-AT level.